Nebenwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.8 · PDF-Seite 14
HOS-209355 · Präparat HOS-154301
Malignancies Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage cfbd7ff22f703ec70c51630dc6f79438e99977d3a3826658d819d24f5d1626a2 · Zeichen 11326–11821 im Abschnitt